GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 6:14 PM ET

    Amgen Inc. rose $1.02 or. 8 percent, to $127.34. Biogen Idec rose $9.68 or 3.0 percent, to $334.64. Celgene Corp. rose $1.97 or 2.3 percent, to $88.41.

  • Cramer: Why the Street is preparing for the worst Wednesday, 13 Aug 2014 | 6:08 PM ET

    Cramer often look inside the market for insights on broad sentiment. And certain things happened on Wednesday that suggest trouble.

  • Vertex to end sales of hepatitis C drug Incivek Wednesday, 13 Aug 2014 | 2:42 PM ET

    Aug 13- Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion.

  • Midday Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 1:50 PM ET

    Amgen Inc. rose$. 83 or. 7 percent, to $127.15. Biogen Idec rose $8.44 or 2.6 percent, to $333.40. Celgene Corp. rose $1.70 or 2.0 percent, to $88.14.

  • Early Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 10:31 AM ET

    Amgen Inc. rose$. 15 or. 1 percent, to $126.47. Biogen Idec rose $3.01 or. 9 percent, to $327.97. Celgene Corp. rose$. 22 or. 2 percent, to $86.66.

  • Lightning Round: El Pollo Loco, Gilead & more Monday, 11 Aug 2014 | 6:49 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Final Glance: Biotechnology companies Monday, 11 Aug 2014 | 6:02 PM ET

    Amgen Inc. rose$. 37 or. 3 percent, to $127.32. Biogen Idec fell $3.71 or 1.1 percent, to $320.34. Celgene Corp. rose$. 37 or. 4 percent, to $86.88.

  • Midday Glance: Biotechnology companies Monday, 11 Aug 2014 | 1:26 PM ET

    Amgen Inc. rose$. 14 or. 1 percent, to $127.09. Biogen Idec fell $2.24 or. 7 percent, to $321.81. Celgene Corp. rose$. 51 or. 6 percent, to $87.02.

  • Early Glance: Biotechnology companies Monday, 11 Aug 2014 | 10:35 AM ET

    Amgen Inc. rose$. 33 or. 3 percent, to $127.28. Biogen Idec fell $1.84 or. 6 percent, to $322.21. Celgene Corp. rose$. 11 or. 1 percent, to $86.62.

  • Final Glance: Biotechnology companies Friday, 8 Aug 2014 | 6:06 PM ET

    Amgen Inc. rose $1.20 or 1.0 percent, to $126.95. Biogen Idec rose $3.45 or 1.1 percent, to $324.05. Celgene Corp. rose $1.29 or 1.5 percent, to $86.51.

  • Midday Glance: Biotechnology companies Friday, 8 Aug 2014 | 1:51 PM ET

    Amgen Inc. rose$. 68 or. 5 percent, to $126.43. Biogen Idec rose $2.73 or. 9 percent, to $323.33. Celgene Corp. rose$. 75 or. 9 percent, to $85.97.

  • Early Glance: Biotechnology companies Friday, 8 Aug 2014 | 10:51 AM ET

    Amgen Inc. rose$. 24 or. 2 percent, to $125.99. Biogen Idec rose $2.04 or. 6 percent, to $322.64. Celgene Corp. rose$. 42 or. 5 percent, to $85.64.

  • Cramer: Dozens of stocks that could work higher Monday, 4 Aug 2014 | 6:56 PM ET

    Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.

  • Aug 1- Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc..

  • July 30- U.S. health insurer Humana Inc reported a lower profit owing to higher costs on Wednesday, as mounting concerns about increased medical spending drove health insurance industry shares lower for a second straight day.

  • July 30- U.S. health insurer Humana Inc said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments. Humana said membership growth and a lower share count due to stock buybacks had helped offset some of the new costs.

  • July 29- Aetna Inc, the third-largest U.S. health insurer, reported a rise in medical costs on Tuesday, raising investor concerns that a long run of low growth in such costs might be ending and pushing shares in the industry lower.

  • New hepatitis drug could be ‘transformational’: CEO Tuesday, 29 Jul 2014 | 11:00 AM ET

    A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.

  • NEW YORK, July 29- With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix. Netflix, along with Gilead Sciences and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports.

  • Investors more wary over tech stock run Monday, 28 Jul 2014 | 10:12 AM ET
    Trader on the floor of the New York Stock Exchange.

    Many so-called momentum stocks have rebounded as economic data have been mixed and volatility remained low. Financial Times reports.